Expect Icatibant to be Saved for Severe Cases of ACEI-Associated Angioedema

April 2015

You'll see more interest in using icatibant (Firazyr, FEAR-ah-zear) for ACE inhibitor-associated angioedema.

This subcutaneous bradykinin receptor antagonist is only FDA approved for hereditary angioedema.

Now new evidence suggests it's also effective for angioedema due to ACEIs. In fact, patients with ACEI-associated angioedema who receive icatibant 30 mg seem to have complete symptom resolution 19 hours sooner...when compared to usual care.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote